Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3τ and CD44 that affect sarcoma incidence and survival

Cancer Research

Volumn 70, Issue 1, 2010, Pages 172-180

  Vazquez, Alexei ^a,b   Grochola, Lukasz F ^c   Bond, Elisabeth E ^c   Levine, Arnold J ^a,b   Taubert, Helge ^d   Müller, Thomas H ^e   Würl, Peter ^f   Bond, Gareth L ^c  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e Institute Springe   (Germany)

^f Malteser St Franziskus Hospital gGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HERMES ANTIGEN; IFOSFAMIDE; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELLULAR STRESS RESPONSE; CHEMOSENSITIVITY; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMORPHIC LOCUS; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; TUMOR CELL LINE;

14-3-3 PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 75149136548     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2218     Document Type: Article

References (37)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
2. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
3. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007;26: 1317-23.
4. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7:979-87.
5. Harris N, Brill E, Shohat O, et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986;6:4650-6.
6. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
7. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
8. Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997;15:887-98.
9. Arva NC, Gopen TR, Talbott KE, et al. A chromatin-associated and transcriptionally inactive p53-2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005;280:26776-87.
10. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.Cancer Res 2007;67:5831-9.
11. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95-107.
12. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
13. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
14. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5: 2606-12.
15. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
16. Kern A, Taubert H, Scheele J, et al. Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Int J Oncol 2002;21:243-9.
17. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
18. Li FP, Strong LC, Fraumeni JF, Jr., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Sciences (New York) 1990;250:1233-8.
19. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
20. Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol 2008;15: 2739-48.
21. Molife R, Lorigan P, MacNeil S. Gender and survival in malignant tumours. Cancer Treat Rev 2001;27:201-9.
22. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-7.
23. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
24. Barbour AP, Reeder JA, Walsh MD, Fawcett J, Antalis TM, Gotley DC. Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. Cancer Res 2003;63:887-92.
25. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 2002;62:2281-6.
26. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 1997;186:1985-96.
27. Dou J, Pan M, Wen P, et al. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 2007;4:467-72.
28. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-65.
29. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
30. Wielenga VJ, Heider KH, Offerhaus GJ, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-6.
31. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998;34: 162-8.
32. Shtivelman E, Bishop JM. Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991;11:5446-53.
33. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009;19:16-23.
34. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16:203-13.
35. Stavridi ES, Chehab NH, Malikzay A, Halazonetis TD. Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest. Cancer Res 2001;61:7030-3.
36. Wang B, Liu K, Lin FT, Lin WC. A role for 14-3-3τ in E2F1 stabilization and DNA damage-induced apoptosis. J Biol Chem 2004;279: 54140-52.
37. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 1998;19:175-8.